03 Profile
Vital Signsby Bridgehead
Hansard to 9 November 2026 · 31,243 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Clinician · Diabetes
Helen O'Neil: no photograph is held, so the clinician plate is shown instead.
Clinician
Helen O'Neil
Senior medicines optimisation pharmacist, North East and North Cumbria Integrated Care Board
1
0
Oct 2026Nov 2026to date
1
press citation on 1 topic since 1 Oct 2026 · last quoted 1 Oct 2026
02 Quoted on · 1 of 29 topics
Helen O'Neil: key facts
- Kind of voice
- Clinician
- Role
- Senior medicines optimisation pharmacist, North East and North Cumbria Integrated Care Board
- Quoted on
- Diabetes
- Tracked press citations
- 1
- Most recently quoted
- 1 Oct 2026
04 The signal · where Helen O'Neil sits on diabetes
Ranked 46= of 100 voices quoted in the press on diabetes, level with 54 others on 1 citation.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1
Douglas TwenefourClinicianHead of Clinical, Diabetes UK11 - 2
Helen KnightRegulatorDirector of Medicines Evaluation, National Institute for Health and Care Excellence (NICE)9 - 3
Parth NarendranAcademicProfessor of Diabetes Medicine; Honorary Consultant Physician (leads the Type 1 Diabetes clinical service at the Queen Elizabeth Hospital Birmingham), University of Birmingham8 - 46=Boaz HirshbergSector leaderRegeneron's head of clinical development for internal medicine1
- 46=Harini SathanapallyClinicianGeneral Practitioner; Doctoral Fellow, University of Leicester1
- 46=Helen O'NeilClinicianSenior medicines optimisation pharmacist, North East and North Cumbria Integrated Care Board1
- 46=Jan JezekClinicianDr, CSO of Arecor1
- 46=Liana BillingsAcademicLead author of the EloraTZP phase 2 study, Endeavor Health (US)1
Showing the leaders and the ranks around 46=, of 100 voices · See every voice on the topic →
05 On the record · press
What Helen O'Neil has said
By outlet · linked articles
- pharmaceutical-journal.com1
Where Helen O'Neil has been quoted
- 01Triple agonist drug retatrutide shows 21% weight loss in patients with diabetespharmaceutical-journal.com · 1 Oct 2026
Verbatim
“Side effects appear similar to other incretin-based therapies, but head-to-head studies are needed to determine its place in treatment pathways.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
- First UK patient treated with NICE approved TeplizumabUniversity of Birmingham
- Branding update for insulin pensDiabetes Research & Wellness Foundation
- DRWF Events: Register now for Diabetes: A Whole Life BlueprintDiabetes Research & Wellness Foundation
Doctors, nurses, allied health professionals and other registered clinicians quoted in a clinical capacity. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 10 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.